Bayer’s Legal and Financial Timelines Converge in April

The coming weeks will be critical for Bayer as two distinct but significant timelines—one legal, one financial—reach pivotal moments. While the company has secured some clarity on the tariff front, its focus is shifting decisively toward a landmark Supreme Court hearing that could reshape its multi-billion dollar glyphosate liability.

On April 27, the US Supreme Court will hear oral arguments on a central legal question: does the federal pesticide law, FIFRA, preempt state-level warning requirements for glyphosat products? A ruling in Bayer’s favor would invalidate a substantial portion of the ongoing litigation. The Trump administration’s Department of Justice has filed a brief supporting the company’s position, marking a reversal from the stance taken under President Biden. Approximately 30 amicus briefs from agricultural groups, health organizations, and plaintiffs’ lawyers underscore the high stakes of the case. A final decision is expected in the second half of June.

Financial Fortitude Amidst Legal Overhang

Despite the legal cloud, Bayer’s management has affirmed its financial guidance for the year. Pharmaceuticals Chief Operating Officer Sebastian Guth stated this week that the company sees no need to adjust its outlook due to recent US import tariffs on pharmaceuticals. A key factor is an existing US-EU trade agreement that caps tariffs on EU-sourced medicines at 15%, a cost Bayer says is already factored into its plans.

The group is targeting EBITDA before special items of 9.6 to 10.1 billion euros for 2026, compared to 9.669 billion euros in the prior year. It also forecasts stable currency-adjusted sales between 45 and 47 billion euros. The company’s net financial debt declined to approximately 29.8 billion euros at the end of 2025, an 8.5% drop from the end of 2024.

Should investors sell immediately? Or is it worth buying Bayer?

Settlement Strategy and Cash Flow Pressure

Parallel to the Supreme Court proceedings, Bayer’s settlement strategy continues. Under the terms of the Missouri settlement, plaintiffs have until June 4 to opt out. A high number of rejections could prompt Bayer to terminate the agreement. Since acquiring Monsanto in 2018, the company has paid out more than $11 billion in settlements and judgments. Management anticipates a negative free cash flow of around 5 billion euros for 2026, reflecting the ongoing financial burden.

In a positive legal development, Kentucky recently became the third US state to pass a law shielding Bayer from certain glyphosate lawsuits, following North Dakota and Georgia. The legislation was enacted despite a veto from the state’s Democratic governor, Andy Beshear.

Key Dates for Shareholders

Investors face a packed calendar. The virtual Annual General Meeting on April 24 will feature a proposed dividend of 0.11 euros per share for 2025, alongside supervisory board elections to replace departing members Paul Achleitner and Colleen Goggins with nominees Marcel Smits and Alfred Stern. The ex-dividend date follows on April 27, with payment scheduled for April 29.

All eyes will then turn to the Q1 earnings report in May, which will provide the management’s first official commentary on the glyphosate litigation ahead of the Supreme Court’s ruling. The stock, currently trading around 40 euros, has rallied roughly 102% from its 52-week low in April 2025 but remains about 18% below its February record high of 49.17 euros. The trajectory of this recovery will likely be determined by the news from Washington in late June.